Targeted Protein Degradation Market Distribution by Type of Degrader, Target Indication, Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World )

As per Roots Analysis, the global targeted protein degradation market is estimated to grow from USD 0.48 billion in the current year to USD 6.94 billion by 2035, at a CAGR of 32% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Degrader

SERD
PROTAC
Molecular Glue

Target Indication

Breast Cancer
Multiple Myeloma

Key Geographical Regions

North America (US and Canada)
Europe (UK, Germany, France, Italy and Spain)
Asia-Pacific (China, South Korea, Japan, India and Australia)
Rest of the World (Brazil and Israel)

TARGETED PROTEIN DEGRADATION MARKET: GROWTH AND TRENDS

Targeted protein degradation (TPD) is an emerging therapeutic modality that has the potential to enable the treatment of difficult-to-treat diseases. While conventional medicines, such as small molecule inhibitors and monoclonal antibodies, target less than 20% of the proteome, TPD provides a novel approach to access the vast majority of unexplored proteins within the proteome. Through TPD, a disease can be addressed by controlling the amount of harmful protein rather than trying to modulate or inhibit its function. The control of protein levels is accomplished with a small molecule drug, called a protein degrader. TPD is a bifunctional small molecule that recruits E3 ubiquitin ligases to the protein of interest and mediates its ubiquitination and subsequent proteolysis by the proteasome.

Targeted Protein Degradation Market - IMG1

Small molecule-mediated selective TPD has several advantages over traditional drug discovery strategies. One of the primary advantages is the high degree of target specificity that can be rapidly validated by leveraging the multiple layers of selectivity in the cellular machinery. Moreover, owing to the fact that the TPD degrader molecules cannot be destroyed, they can cause the destruction of many copies of harmful proteins and reduce systemic drug exposure. In addition, it can counteract increased target protein expression by inhibiting the protein function. It is worth noting that a single protein degrader has the ability to potentially eliminate multiple disease-causing proteins through proteasome degradation of the target protein. Owing to the above-mentioned advantages and the ongoing pace of technological advancements, the targeted protein degradation market is poised to experience noteworthy growth during the forecast period.

TARGETED PROTEIN DEGRADATION MARKET: KEY INSIGHTS

The report delves into the current state of the targeted protein degradation market and identifies potential growth opportunities within industry. Some key findings from the report include:

285+ targeted protein degradation therapies are either approved or being investigated in different stages of development; the market landscape features the presence of both established players and new entrants.
Over 20% of the targeted protein degraders being evaluated are molecular glues; of these, more than 70% are intended for the treatment of oncological disorders.
Over 35% of the technologies are focused on developing PROTACs; of these, 38% have the capability to identify the targets utilizing CADD analysis.

Targeted Protein Degradation Market - IMG2

At present, around 85 innovative targeted protein degradation technologies are available for developing stable and efficacious degraders; further, majority of the technology providers are start-ups / small businesses.
Around 250 clinical trials (with around 63,000 enrolled patients) are currently underway to investigate targeted protein degradation therapies intended for treatment of various diseases, across different geographies.
Since 2019, grants worth over USD 165 million have been awarded by NIH; ~80% of these grants were awarded for a support period of 1-4 years.

Targeted Protein Degradation Market - IMG3

In the last five years, several articles have been published in various high-impact journals; such publications have garnered more interest in the Asia-Pacific region.
More than 985 patents have been filed for targeted protein degraders and related technologies by industry and non-industry players, to protect intellectual property generated within this field.
The rising interest is reflected in the wide array of partnerships established between various stakeholders in the recent past; 25% of the deals were focused on research and development of novel protein degraders.
Several investors have realized the opportunity within the domain of targeted protein degradation and invested around USD 13.5 billion across various funding rounds in the past six years.
Owing to the protein degraders ability to degrade the undruggable targets selectively, the targeted protein degradation therapies market is anticipated to witness an annualized growth of 32% over the next decade.

Targeted Protein Degradation Market - IMG4

The estimated market opportunity is projected to be distributed across different countries, especially in the US, France, Spain, the UK and China.

TARGETED PROTEIN DEGRADATION MARKET: KEY SEGMENTS

SERD Segment Occupies the Largest Share of the Targeted Protein Degradation Market

Based on the type of degrader, the market is segmented into SERD, PROTAC and molecular glue. At present, the SERD segment holds the maximum share of the targeted protein degradation market owing to the approval of elacestrant (ORSERDU), an oral SERD for metastatic breast cancer. Additionally, the PROTAC segment is likely to grow at a faster pace during the forecasted period.

By Target Indication, Breast Cancer is the Fastest Growing Segment of the Global Targeted Protein Degradation Market

Based on the target indication, the market is segmented into breast cancer and multiple myeloma. Currently, the breast cancer segment captures the highest proportion of the targeted protein degradation market. This trend is likely to remain the same in the future owing to the increasing prevalence of breast cancer, with over 12.5% of all newly diagnosed cases. Further, targeted protein degradation market for the breast cancer segment is likely to grow at a relatively higher CAGR during the forecast period.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. Currently, North America dominates the targeted protein degradation market and accounts for the largest revenue share. Further, the market in Asia-Pacific is expected to grow at a higher CAGR in the coming years.

Example Players in the Targeted Protein Degradation Market

Arvinas
AstraZeneca
BeiGene
Bristol-Myers Squibb
C4 Therapeutics
Eisai Therapeutics
InnoCare Pharma
Kangpu Biopharmaceuticals
Kintor Pharmaceutical
Loxo Oncology
Medivir
Monte Rosa Therapeutics
Olema Oncology
Radius Health
Ranok Therapeutics
Roche
Sanofi
Zentalis Pharmaceuticals

TARGETED PROTEIN DEGRADATION MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the targeted protein degradation market, focusing on key market segments, including [A] type of degrader, [B] target indication, and [C] key geographical regions.
Targeted Protein Degradation Therapies Market Landscape: A comprehensive evaluation of the companies engaged in targeted protein degradation therapies market, based on several relevant parameters, such as [A] stage of development, [B] type of degrader, [C] biological target, [D] target enzyme, [E] target indication and [F] therapeutic area. Additionally, a comprehensive evaluation of the targeted protein degradation therapy developers, based on several relevant parameters, such as [G] year of establishment, [H] company size, [I] location of headquarters and [J] most active players.
Targeted Protein Degradation Technologies Market Landscape: A comprehensive evaluation of the companies engaged in targeted protein degradation technologies market, based on several relevant parameters, such as [A] type of degrader developed, [B] protein degradation pathway, [C] site of degraded protein, [D] therapeutic area, [E] discovery step supported and [F] availability of computational modeling ability. Additionally, a comprehensive evaluation of the companies offering targeted protein degradation technologies, based on several relevant parameters, such as [G] year of establishment, [H] company size and [I] location of headquarters.
Company Profiles: In-depth profiles of key companies engaged in the targeted protein degradation market, focusing on [A] overview of the company, [B] financial information (if available), [C] technology portfolio, [D] pipeline overview and [E] recent developments and an [F] informed future outlook.
Clinical Trial Analysis: An insightful analysis of clinical trials related to targeted protein degradation, based on several parameters, such as [A] trial registration year, [B] number of patients enrolled, [C] trial phase, [D] trial status, [E] patient gender, [F] target indication, [G] study design, [H] most active sponsor / collaborator and [I] geography.
Grants Analysis: A comprehensive assessment of grants that have been awarded to research institutes in the targeted protein degradation domain, based on various relevant parameters, such as [A] year of grant award, [B] amount awarded, [C] funding institute centers, [D] support period, [E] type of grant application, [F] purpose of grant award, [G] activity code, [H] study section involved, [I] popular NIH departments, [J] prominent program officers, [k] popular recipient organizations and [L] distribution of popular recipient organizations by states in the US.
Patent Analysis: An in-depth analysis of patents filed / granted till date in the targeted protein degradation domain, based on various relevant parameters, such as [A] type of patent, [B] patent application year, [C] patent publication year, [D] patent jurisdiction, [E] CPC symbols, [F] type of applicant, [G] individual patent assignees, [H] patent age, [I] patent benchmarking, and [J] patent valuation analysis.
Publication Analysis: An insightful analysis of peer-reviewed scientific articles related to research on targeted protein degradation, based on various relevant parameters, such as [A] year of publication, [B] type of publication, [C] key journal, [D] most active publisher, [E] most active copyright holder, [F] most popular keywords, [G] therapeutic area and [H] key geographical regions.
Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the targeted protein degradation market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of partner, [D] type of degrader, [E] most active players and [F] geographical distribution of the partnership activity.
Funding and Investments: An in-depth analysis of the fundings raised by targeted protein degradation companies, based on relevant parameters, such as [A] year-wise trend of funding instances, [B] amount invested, [C] type of funding, [D] geographical analysis, [E] leading players and [F] leading investors.
Market Impact Analysis: A thorough analysis of various factors, such as drivers, restraints, opportunities, and existing challenges that are likely to impact market growth.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

Product Code: RA100259A

1. PREFACE

1.1. Market Overview

1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. COVID Impact
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
- 3.2.1. Time Period
  - 3.2.1.1. Historical Trends
  - 3.2.1.2. Current and Future Estimates
- 3.2.2. Currency Coverage and Foreign Exchange Rate
  - 3.2.2.1. Major Currencies Affecting the Market
  - 3.2.2.2. Factors affecting Currency Fluctuations and Foreign Exchange Rates
  - 3.2.2.3. Impact of Foreign Exchange Rate Volatility on Market
  - 3.2.2.4. Strategies For Mitigating Foreign Exchange Risk
- 3.2.3. Trade Policies
  - 3.2.3.1. Impact of Trade Barriers on the Market
  - 3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
- 3.2.4. Recession
  - 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
  - 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 3.2.5. Inflation
  - 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview
5.2. Overview of Targeted Protein Degradation
- 5.2.1. Historical Evolution of Targeted Protein Degraders
5.3. Targeted Protein Degrader Pathway
5.4. Types of Protein Degraders
- 5.4.1. Proteolysis Targeting Chimeras (PROTACs)
- 5.4.2. Endosome Targeting Chimeras (ENDTACs)
- 5.4.3. Photochemically Targeted Chimeras (PHOTACs)
- 5.4.4. Hydrophobic Tags
- 5.4.5. Immunomodulatory Imide Drugs (IMiDs)
- 5.4.6. Molecular Glues
- 5.4.7. Selective Hormone Receptor Degraders (SHRDs)
- 5.4.8. Specific and Nongenetic inhibitor-of-apoptosis proteins (IAP)- Dependent Protein Erasers (SNIPERs)
- 5.4.9. DUB Inhibitors
- 5.4.10. Other Protein Degraders
5.5. Targeted Therapeutic Areas
5.6. Benefits and Challenges Associated with Targeted Protein Degradation
5.7. Future Perspectives

6. MARKET LANDSCAPE: TARGETED PROTEIN DEGRADATION THERAPIES

6.1. Chapter Overview
6.2. Targeted Protein Degradation Therapies: Overall Market Landscape
- 6.2.1. Analysis by Stage of Development
- 6.2.2. Analysis by Type of Degrader
- 6.2.3. Analysis by Biological Target
- 6.2.4. Analysis by Target Enzyme
- 6.2.5. Analysis by Target Indication
- 6.2.6. Analysis by Therapeutic Area
6.3. Targeted Protein Degradation Therapy Developers: Overall Market Landscape
- 6.3.1. Analysis by Year of Establishment
- 6.3.2. Analysis by Company Size
- 6.3.3. Analysis by Location of Headquarters (Region)
- 6.3.4. Analysis by Year of Establishment and Location of Headquarters (Region)
- 6.3.5. Analysis by Company Size and Location of Headquarters (Region)
- 6.3.6. Most Active Developers: Distribution by Number of Therapies and Stage of Development

7. MARKET LANDSCAPE: TARGETED PROTEIN DEGRADATION TECHNOLOGIES

7.1. Chapter Overview
7.2. Targeted Protein Degradation Technologies: Overall Market Landscape
- 7.2.1. Analysis by Type of Degrader Developed
- 7.2.2. Analysis by Protein Degradation Pathway
- 7.2.3. Analysis by Site of Degraded Protein
- 7.2.4. Analysis by Therapeutic Area
- 7.2.5. Analysis by Discovery Step Supported
- 7.2.6. Analysis by Availability of Computational Modeling Ability
- 7.2.7. Analysis by Year of Establishment
- 7.2.8. Analysis by Company Size
- 7.2.9. Analysis by Location of Headquarters (Region)
- 7.2.10. Analysis by Year of Establishment and Location of Headquarters (Region)
- 7.2.11. Analysis by Company Size and Location of Headquarters (Region)

8. COMPANY PROFILES

8.1. Chapter Overview
8.2. Detailed Company Profiles of Prominent Players
- 8.2.1. Arvinas
  - 8.2.1.1. Company Overview
  - 8.2.1.2. Financial Information
  - 8.2.1.3. Technology Portfolio
  - 8.2.1.4. Pipeline Overview
  - 8.2.1.5. Recent Developments and Future Outlook
- 8.2.2. Bristol-Myers Squibb
  - 8.2.2.1. Company Overview
  - 8.2.2.2. Financial Information
  - 8.2.2.3. Technology Portfolio
  - 8.2.2.4. Pipeline Overview
  - 8.2.2.5. Recent Developments and Future Outlook
- 8.2.3. C4 Therapeutics
  - 8.2.3.1. Company Overview
  - 8.2.3.2. Financial Information
  - 8.2.3.3. Technology Portfolio
  - 8.2.3.4. Pipeline Overview
  - 8.2.3.5. Recent Developments and Future Outlook
- 8.2.4. Loxo Oncology
  - 8.2.4.1. Company Overview
  - 8.2.4.2. Pipeline Overview
  - 8.2.4.3. Recent Developments and Future Outlook
- 8.2.5. Olema Oncology
  - 8.2.5.1. Company Overview
  - 8.2.5.2. Pipeline Overview
  - 8.2.5.3. Recent Developments and Future Outlook
- 8.2.6. Radius Health
  - 8.2.6.1. Company Overview
  - 8.2.6.2. Financial Information
  - 8.2.6.3. Pipeline Overview
  - 8.2.6.4. Recent Developments and Future Outlook
- 8.2.7. AstraZeneca
  - 8.2.7.1. Company Overview
  - 8.2.7.2. Financial Information
  - 8.2.7.3. Pipeline Overview
  - 8.2.7.4. Recent Developments and Future Outlook
- 8.2.8. Roche
  - 8.2.8.1. Company Overview
  - 8.2.8.2. Financial Information
  - 8.2.8.3. Pipeline Overview
  - 8.2.8.4. Recent Developments and Future Outlook
8.3. Short Profiles of Other Prominent Players
- 8.3.1. BeiGene
  - 8.3.1.1. Company Overview
  - 8.3.1.2. Pipeline Overview
- 8.3.2. InnoCare Pharma
  - 8.3.2.1. Company Overview
  - 8.3.2.2. Technology Portfolio
  - 8.3.2.3. Pipeline Overview
- 8.3.3. Kangpu Biopharmaceuticals
  - 8.3.3.1. Company Overview
  - 8.3.3.2. Technology Portfolio
  - 8.3.3.3. Pipeline Overview
- 8.3.4. Kintor Pharmaceuticals
  - 8.3.4.1. Company Overview
  - 8.3.4.2. Technology Portfolio
  - 8.3.4.3. Pipeline Overview
- 8.3.5. Medivir
  - 8.3.5.1. Company Overview
  - 8.3.5.2. Technology Portfolio
  - 8.3.5.3. Pipeline Overview
- 8.3.6. Monte Rosa Therapeutics
  - 8.3.6.1. Company Overview
  - 8.3.6.2. Technology Portfolio
  - 8.3.6.3. Pipeline Overview
- 8.3.7. Ranok Therapeutics
  - 8.3.7.1. Company Overview
  - 8.3.7.2. Technology Portfolio
  - 8.3.7.3. Pipeline Overview
- 8.3.8. Sanofi
  - 8.3.8.1. Company Overview
  - 8.3.8.2. Pipeline Overview
- 8.3.9. Zentalis Pharmaceuticals
  - 8.3.9.1. Company Overview
  - 8.3.9.2. Technology Portfolio
  - 8.3.9.3. Pipeline Overview
- 8.3.10. Eisai Therapeutics
  - 8.3.10.1. Company Overview
  - 8.3.10.2. Pipeline Overview

9. CLINICAL TRIAL ANALYSIS

9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Targeted Protein Degradation: Clinical Trial Analysis
- 9.3.1. Analysis by Trial Registration Year
- 9.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
- 9.3.3. Analysis by Trial Phase
- 9.3.4. Analysis of Number of Patients Enrolled by Trial Phase
- 9.3.5. Analysis by Trial Registration Year and Trial Phase
- 9.3.6. Analysis by Trial Status
- 9.3.7. Analysis by Patient Gender
- 9.3.8. Analysis by Target Indication
- 9.3.9. Analysis by Study Design
  - 9.3.9.1. Analysis by Type of Trial Masking
  - 9.3.9.2. Analysis by Type of Intervention Model
  - 9.3.9.3. Analysis by Trial Purpose
  - 9.3.9.4. Analysis by Design Allocation
- 9.3.10. Most Active Sponsor / Collaborator: Analysis by Number of Registered Trials
  - 9.3.10.1. Analysis by Leading Industry Players
  - 9.3.10.2. Analysis by Leading Non-Industry Players
- 9.3.11. Analysis by Geography
  - 9.3.11.1. Analysis of Clinical Trials by Trial Status and Geography
  - 9.3.11.2. Analysis of Patients Enrolled by Trial Status and Geography

10. GRANTS ANALYSIS

10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Targeted Protein Degradation: Grants Analysis
- 10.3.1. Analysis by Year of Grant Award
- 10.3.2. Analysis by Amount Awarded
- 10.3.3. Analysis by Funding Institute Center
- 10.3.4. Analysis by Support Period
- 10.3.5. Analysis by Funding Institute Center and Support Period
- 10.3.6. Analysis by Type of Grant Application
- 10.3.7. Analysis by Purpose of Grant Award
- 10.3.8. Analysis by Activity Code
- 10.3.9. Analysis by Study Section Involved
- 10.3.10. Most Popular NIH Departments: Analysis by Number of Grants
- 10.3.11. Prominent Program Officers: Analysis by Number of Grants
- 10.3.12. Popular Recipient Organizations: Analysis by Number of Grants
- 10.3.13. Popular Recipient Organizations: Analysis by Grant Amount
- 10.3.14. Popular Recipient Organizations: Analysis by States in the US

11. PATENT ANALYSIS

11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Targeted Protein Degradation: Patents Analysis
- 11.3.1. Analysis by Patent Publication Year
- 11.3.2. Analysis by Patent Application Year
- 11.3.3. Analysis of Granted Patents and Patent Applications by Publication Year
- 11.3.4. Analysis by Patent Jurisdiction
- 11.3.5. Analysis by CPC Symbols
- 11.3.6. Analysis by Type of Applicant
- 11.3.7. Leading Industry Players: Analysis by Number of Patents
- 11.3.8. Leading Non-Industry Players: Analysis by Number of Patents
- 11.3.9. Leading Patent Assignees: Analysis by Number of Patents
11.4. Patent Benchmarking Analysis
- 11.4.1. Analysis of Patent Characteristics (CPC Codes) by Leading Industry Players
11.5. Patent Valuation
11.6. Leading Patents by Number of Citations

12. PUBLICATION ANALYSIS

12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Targeted Protein Degradation: Publication Analysis
- 12.3.1. Analysis by Year of Publication
- 12.3.2. Analysis by Type of Publication
- 12.3.3. Key Journals: Analysis by Number of Publications
- 12.3.4. Key Journals: Analysis by Journal Impact Factor
- 12.3.5. Most Active Publisher: Analysis by Number of Publications
- 12.3.6. Most Active Copyright Holder: Analysis by Number of Publications
- 12.3.7. Analysis by Emerging Focus Area
- 12.3.8. Analysis by Therapeutic Area
- 12.3.9. Analysis by Geography

13. PARTNERSHIPS AND COLLABORATIONS

13.1. Chapter Overview
13.2. Partnership Models
13.3. Targeted Protein Degradation: Partnerships and Collaborations
- 13.3.1. Analysis by Year of Partnership
- 13.3.2. Analysis by Type of Partnership
- 13.3.3. Analysis by Year and Type of Partnership
- 13.3.4. Analysis by Type of Partner
- 13.3.5. Analysis by Type of Degrader
- 13.3.6. Most Active Players: Analysis by Number of Partnerships
13.4. Analysis by Geography
- 13.4.1. Local and International Agreements
- 13.4.2. Intercontinental and Intracontinental Agreements

14. FUNDING AND INVESTMENTS

14.1. Chapter Overview
14.2. Funding Models
14.3. Targeted Protein Degradation: Funding and Investments
- 14.3.1. Analysis by Year of Funding
- 14.3.2. Analysis by Amount Invested
- 14.3.3. Analysis by Type of Funding
- 14.3.4. Analysis by Amount Invested and Type of Funding
- 14.3.5. Analysis of Amount Invested by Year and Type of Funding
- 14.3.6. Analysis by Geography
- 14.3.7. Most Active Players
  - 14.3.7.1. Analysis by Number of Funding Instances
  - 14.3.7.2. Analysis by Amount Invested
- 14.3.8. Leading Investors: Analysis by Number of Funding Instances
14.4. Concluding Remarks

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

15.1. Chapter Overview
15.2. Market Drivers
15.3. Market Restraints
15.4. Market Opportunities
15.5. Market Challenges
15.6. Conclusion

16. GLOBAL TARGETED PROTEIN DEGRADATION THERAPIES MARKET

16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Global Targeted Protein Degradation Therapies Market, Forecasted Estimates (Till 2035)
- 16.3.1. Scenario Analysis
  - 16.3.1.1. Conservative Scenario
  - 16.3.1.2. Optimistic Scenario
16.4. Key Market Segmentations

17. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, BY TYPE OF DEGRADER

17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Targeted Protein Degradation Therapies Market: Distribution by Type of Degrader
- 17.3.1. Targeted Protein Degradation Therapies Market for SERDs: Forecasted Estimates (Till 2035)
- 17.3.2. Targeted Protein Degradation Therapies Market for PROTACs: Forecasted Estimates (Till 2035)
- 17.3.3. Targeted Protein Degradation Therapies Market for Molecular Glues: Forecasted Estimates (Till 2035)
17.4. Data Triangulation and Validation

18. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, BY TARGET INDICATION

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Targeted Protein Degradation Therapies Market: Distribution by Target Indication
- 18.3.1. Targeted Protein Degradation Therapies Market for Breast Cancer: Forecasted Estimates (Till 2035)
- 18.3.2. Targeted Protein Degradation Therapies Market for Multiple Myeloma: Forecasted Estimates (Till 2035)
18.4. Data Triangulation and Validation

19. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, BY KEY GEOGRAPHICAL REGIONS

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Targeted Protein Degradation Therapies Market: Distribution by Key Geographical Regions
- 19.3.1. Targeted Protein Degradation Therapies Market in North America: Forecasted Estimates (Till 2035)
  - 19.3.1.1. Targeted Protein Degradation Therapies Market in US: Forecasted Estimates (Till 2035)
  - 19.3.1.2. Targeted Protein Degradation Therapies Market in Canada: Forecasted Estimates (Till 2035)
- 19.3.2. Targeted Protein Degradation Therapies Market in Europe: Forecasted Estimates (Till 2035)
  - 19.3.2.1. Targeted Protein Degradation Therapies Market in UK: Forecasted Estimates (Till 2035)
  - 19.3.2.2. Targeted Protein Degradation Therapies Market in Germany: Forecasted Estimates (Till 2035)
  - 19.3.2.3. Targeted Protein Degradation Therapies Market in France: Forecasted Estimates (Till 2035)
  - 19.3.2.4. Targeted Protein Degradation Therapies Market in Italy: Forecasted Estimates (Till 2035)
  - 19.3.2.5. Targeted Protein Degradation Therapies Market in Spain: Forecasted Estimates (Till 2035)
- 19.3.3. Targeted Protein Degradation Therapies Market in Asia-Pacific: Forecasted Estimates (Till 2035)
  - 19.3.3.1. Targeted Protein Degradation Therapies Market in China: Forecasted Estimates (Till 2035)
  - 19.3.3.2. Targeted Protein Degradation Therapies Market in South Korea: Forecasted Estimates (Till 2035)
  - 19.3.3.3. Targeted Protein Degradation Therapies Market in India: Forecasted Estimates (Till 2035)
  - 19.3.3.4. Targeted Protein Degradation Therapies Market in Japan: Forecasted Estimates (Till 2035)
  - 19.3.3.5. Targeted Protein Degradation Therapies Market in Australia: Forecasted Estimates (Till 2035)
- 19.3.4. Targeted Protein Degradation Therapies Market in Rest of the World: Forecasted Estimates (Till 2035)
  - 19.3.4.1. Targeted Protein Degradation Therapies Market in Brazil: Forecasted Estimates (Till 2035)
  - 19.3.4.2. Targeted Protein Degradation Therapies Market in Israel: Forecasted Estimates (Till 2035)
19.5. Data Triangulation and Validation

20. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, SALES FORECAST OF DRUGS

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Commercialized Targeted Protein Degradation Therapies Market: Sales Forecast
- 20.3.1. RAD1901 / Elacestrant / Orserdu Sales Forecast
20.4. Phase III Targeted Protein Degradation Therapies Market: Sales Forecast
- 20.4.1. Vepdegestrant / ARV-471 Sales Forecast
- 20.4.2. Camizestrant / AZD9833 Sales Forecast
- 20.4.3. CC-92480 / BMS-986348 / Mezigdomide Sales Forecast
- 20.4.4. LY3484356 / Imlunestrant Sales Forecast
- 20.4.5. OP-1250 / OP-1250-301 / Palazestrant Sales Forecast
20.5. Data Triangulation and Validation

21. GLOBAL TARGETED PROTEIN DEGRADATION TECHNOLOGIES MARKET

21.1. Chapter Overview
21.2. Key Assumptions
21.3. Forecast Methodology
21.4. Global Targeted Protein Degradation Technologies Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 21.4.1. Scenario Analysis
  - 21.4.1.1. Conservative Scenario
  - 21.4.1.2. Optimistic Scenario
21.5. Targeted Protein Degradation Technologies Market: Distribution by Type of Payment Model Employed
- 21.5.1. Targeted Protein Degradation Technologies Market for Upfront Payments: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 21.5.2. Targeted Protein Degradation Technologies Market for Milestone Payments: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
21.6. Data Triangulation and Validation

22. EXECUTIVE INSIGHTS

22.1. Chapter Overview
22.2. GlycoEra
- 22.2.1. Company Snapshot
- 22.2.2. Interview Transcript: Ganesh Kaundinya, Chief Executive Officer and President
22.3. Polyprox Therapeutics
- 22.3.1. Company Snapshot
- 22.3.2. Interview Transcript: Laura Itzhaki, Chief Scientific Officer and Founder
22.4. Xios Therapeutics
- 22.4.1. Company Snapshot
- 22.4.2. Interview Transcript: Louise Bergeron, Former Chief Scientific Officer and Former Vice President, Research
22.5. Mission Therapeutics
- 22.5.1. Company Snapshot
- 22.5.2. Interview Transcript: Paul Wallace, Former Chief Business Officer
22.6. Ubiquigent
- 22.6.1. Company Snapshot
- 22.6.2. Interview Transcript: Jason Brown, Former Scientific and Business Development Director
22.7. Almac Discovery
- 22.7.1. Company Snapshot
- 22.7.2. Interview Transcript: Martin Wales, Former Vice President, Business Development and Licensing and Gerald Gavory, Former Vice President, Biology
22.8. University of Delaware
- 22.8.1. Company Snapshot
- 22.8.2. Interview Transcript: Zhihao Zhuang (Professor)
22.9 Francis Crick Institute
- 22.9.1. Company Snapshot
- 22.9.2. Interview Transcript: Katrin Rittinger (Group Leader)
22.10 Anonymous
- 22.10.1. Interview Transcript: Chief Scientific Officer
22.11 Anonymous
- 22.11.1. Interview Transcript: Director of Oncology Research

23. CONCLUSION

24. APPENDIX 1: TABULATED DATA

25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

26. APPENDIX 3: LIST OF FUNDING AND INVESTMENTS

Product Code: RA100259A

List of Tables

Table 6.1 Targeted Protein Degradation Therapies: Information on Developer, Stage of Development and Type of Degrader
Table 6.2 Targeted Protein Degradation Therapies: Information on Biological Target, Target Enzyme, Target Indication and Therapeutic Area
Table 6.3 Targeted Protein Degradation Therapy Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 7.1 Targeted Protein Degradation Technologies: Information on Type of Degrader Developed, Protein Degradation Pathway and Site of Degraded Protein
Table 7.2 Targeted Protein Degradation Technologies: Information on Therapeutic Area
Table 7.3 Targeted Protein Degradation Technologies: Information on Discovery Step Supported and CADD Ability
Table 7.4 Targeted Protein Degradation Technology Providers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 8.1 List of Targeted Protein Degradation Therapy Developers Profiled
Table 8.2 Arvinas: Company Overview
Table 8.3 Arvinas: Technology Portfolio
Table 8.4 Arvinas: Pipeline Overview
Table 8.5 Arvinas: Recent Developments and Future Outlook
Table 8.6 Bristol-Myers Squibb: Company Overview
Table 8.7 Bristol-Myers Squibb: Technology Portfolio
Table 8.8 Bristol-Myers Squibb: Pipeline Overview
Table 8.9 Bristol-Myers Squibb: Recent Developments and Future Outlook
Table 8.10 C4 Therapeutics: Company Overview
Table 8.11 C4 Therapeutics: Technology Portfolio
Table 8.12 C4 Therapeutics: Pipeline Overview
Table 8.13 C4 Therapeutics: Recent Developments and Future Outlook
Table 8.14 Loxo Oncology: Company Overview
Table 8.15 Loxo Oncology: Pipeline Overview
Table 8.16 Olema Oncology: Company Overview
Table 8.17 Olema Oncology: Pipeline Overview
Table 8.18 Olema Oncology: Recent Developments and Future Outlook
Table 8.19 Radius Health: Company Overview
Table 8.20 Radius Health: Pipeline Overview
Table 8.21 Radius Health: Recent Developments and Future Outlook
Table 8.22 AstraZeneca: Company Overview
Table 8.23 AstraZeneca: Pipeline Overview
Table 8.24 Roche: Company Overview
Table 8.25 Roche: Pipeline Overview
Table 8.26 BeiGene: Company Overview
Table 8.27 BeiGene: Pipeline Overview
Table 8.28 InnoCare Pharma: Company Overview
Table 8.29 InnoCare Pharma: Technology Portfolio
Table 8.30 InnoCare Pharma: Pipeline Overview
Table 8.31 Kangpu Biopharmaceuticals: Company Overview
Table 8.32 Kangpu Biopharmaceuticals: Technology Portfolio
Table 8.33 Kangpu Biopharmaceuticals: Pipeline Overview
Table 8.34 Kintor Pharmaceutical: Company Overview
Table 8.35 Kintor Pharmaceutical: Technology Portfolio
Table 8.36 Kintor Pharmaceutical: Pipeline Overview
Table 8.37 Medivir: Company Overview
Table 8.38 Medivir: Technology Portfolio
Table 8.39 Medivir: Pipeline Overview
Table 8.40 Monte Rosa Therapeutics: Company Overview
Table 8.41 Monte Rosa Therapeutics: Technology Portfolio
Table 8.42 Monte Rosa Therapeutics: Pipeline Overview
Table 8.43 Ranok Therapeutics: Company Overview
Table 8.44 Ranok Therapeutics: Technology Portfolio
Table 8.45 Ranok Therapeutics: Pipeline Overview
Table 8.46 Sanofi: Company Overview
Table 8.47 Sanofi: Pipeline Overview
Table 8.48 Zentalis Pharmaceuticals: Company Overview
Table 8.49 Zentalis Pharmaceuticals: Technology Portfolio
Table 8.50 Zentalis Pharmaceuticals: Pipeline Overview
Table 8.51 Eisai Therapeutics: Company Overview
Table 8.52 Eisai Therapeutics: Pipeline Overview
Table 11.1 Patent Analysis: Top CPC Sections
Table 11.2 Patent Analysis: Top CPC Symbols
Table 11.3 Patent Analysis: Top CPC Codes
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.6 Patent Portfolio: List of Leading Patents (By Highest Relative Valuation)
Table 11.7 Patent Portfolio: List of Leading Patents (By Number of Citations)
Table 13.1 Targeted Protein Degradation: List of Partnerships and Collaborations
Table 13.2 Partnerships and Collaborations: Information on Type of Agreement (Country and Region)
Table 14.1 Targeted Protein Degradation: List of Funding and Investments, Since 2018
Table 16.1 List of Targeted Protein Degradation Therapies Forecasted
Table 21.1 Targeted Protein Degradation Technologies: Average Upfront Payment and Average Milestone Payment, Since 2015 (USD Million)
Table 21.2 Library Licensing Deal: Tranches of Milestone Payments
Table 22.1 GlycoEra: Company Snapshot
Table 22.2 Polyprox Therapeutics: Company Snapshot
Table 22.3 Xios Therapeutics: Company Snapshot
Table 22.4 Mission Therapeutics: Company Snapshot
Table 22.5 Ubiquigent: Company Snapshot
Table 22.6 Almac Discovery: Company Snapshot
Table 22.7 University of Delaware: Company Snapshot
Table 22.8 Francis Crick Institute: Company Snapshot
Table 22.9 Anonymous: Company Snapshot
Table 22.10 Anonymous: Company Snapshot
Table 24.1 Targeted Protein Degradation Therapies: Distribution by Stage of Development
Table 24.2 Targeted Protein Degradation Technologies: Distribution by Type of Degrader
Table 24.3 Targeted Protein Degradation Therapies: Distribution by Biological Target
Table 24.4 Targeted Protein Degradation Therapies: Distribution by Target Enzyme
Table 24.5 Targeted Protein Degradation Therapies: Distribution by Target Indication
Table 24.6 Targeted Protein Degradation Therapies: Distribution by Therapeutic Area
Table 24.7 Targeted Protein Degradation Therapy Developers: Distribution by Year of Establishment
Table 24.8 Targeted Protein Degradation Therapy Developers: Distribution by Company Size
Table 24.9 Targeted Protein Degradation Therapy Developers: Distribution by Location of Headquarters (Region)
Table 24.10 Targeted Protein Degradation Therapy Developers: Distribution by Year of Establishment and Location of Headquarters (Region)
Table 24.11 Targeted Protein Degradation Therapy Developers: Distribution by Company Size and Location of Headquarters (Region)
Table 24.12 Most Active Developers: Distribution by Number of Therapies and Stage of Development
Table 24.13 Targeted Protein Degradation Technologies: Distribution by Type of Degrader Developed
Table 24.14 Targeted Protein Degradation Technologies: Distribution by Protein Degradation Pathway
Table 24.15 Targeted Protein Degradation Technologies: Distribution by Site of Degraded Protein
Table 24.16 Targeted Protein Degradation Therapies: Distribution by Therapeutic Area
Table 24.17 Targeted Protein Degradation Therapies: Distribution by Discovery Step Supported
Table 24.18 Targeted Protein Degradation Technologies: Distribution by Availability of Computational Modeling Ability
Table 24.19 Targeted Protein Degradation Technology Providers: Distribution by Year of Establishment
Table 24.20 Targeted Protein Degradation Technology Providers: Distribution by Company Size
Table 24.21 Targeted Protein Degradation Technology Providers: Distribution by Location of Headquarters (Region)
Table 24.22 Targeted Protein Degradation Technology Providers: Distribution by Year of Establishment and Location of Headquarters (Region)
Table 24.23 Targeted Protein Degradation Technology Providers: Distribution by Company Size and Location of Headquarters (Region)
Table 24.24 Arvinas: Annual Revenues, Since FY 2019 (USD Million)
Table 24.25 Bristol-Myers Squibb: Annual Revenues, Since FY 2019 (USD Billion)
Table 24.26 C4 Therapeutics: Annual Revenues, Since FY 2019 (USD Million)
Table 24.27 Radius Health: Annual Revenues, Since FY 2019 (USD Million)
Table 24.28 AstraZeneca: Annual Revenues, Since FY 2019 (USD Billion)
Table 24.29 Roche: Annual Revenues, Since FY 2019 (CHF Billion)
Table 24.30 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2019
Table 24.31 Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year, Since 2019
Table 24.32 Clinical Trial Analysis: Distribution by Trial Phase
Table 24.33 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Table 24.34 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Since 2019
Table 24.35 Clinical Trial Analysis: Distribution by Trial Status
Table 24.36 Clinical Trial Analysis: Distribution by Patient Gender
Table 24.37 Clinical Trial Analysis: Distribution by Target Indication
Table 24.38 Clinical Trial Analysis: Distribution by Type of Trial Masking
Table 24.39 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 24.40 Clinical Trial Analysis: Distribution by Trial Purpose
Table 24.41 Clinical Trial Analysis: Distribution by Distribution by Design Allocation
Table 24.42 Leading Industry Players: Distribution by Number of Registered Trials
Table 24.43 Leading Non-Industry Players: Distribution by Number of Registered Trials
Table 24.44 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Table 24.45 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Table 24.46 Grants Analysis: Cumulative Year-wise Trend, Since 2019
Table 24.47 Grants Analysis: Cumulative Year-wise Trend of Grants by Amount Awarded (USD Million)
Table 24.48 Grants Analysis: Distribution by Funding Institute Center
Table 24.49 Grants Analysis: Distribution by Funding Institute Center and Support Period
Table 24.50 Grants Analysis: Distribution by Support Period
Table 24.51 Grants Analysis: Distribution by Type of Grant Application
Table 24.52 Grants Analysis: Distribution by Purpose of Grant Award
Table 24.53 Grants Analysis: Distribution by Activity Code (Series)
Table 24.54 Grants Analysis: Distribution by Activity Code
Table 24.55 Grants Analysis: Distribution by Study Section Involved
Table 24.56 Most Popular NIH Departments: Distribution by Number of Grants
Table 24.57 Prominent Program Officers: Distribution by Number of Grants
Table 24.58 Popular Recipient Organizations: Distribution by Number of Grants
Table 24.59 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
Table 24.60 Popular Recipient Organizations: Distribution by States in the US
Table 24.61 Patent Analysis: Distribution by Type of Patent
Table 24.62 Patent Analysis: Distribution by Patent Publication Year, Since 2019
Table 24.63 Patent Analysis: Distribution by Patent Application Year, Since Pre-2019
Table 24.64 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, Since 2019
Table 24.65 Patent Analysis: Distribution by Patent Jurisdiction
Table 24.66 Patent Analysis: Cumulative Year-wise Trend by Type of Applicant
Table 24.67 Leading Industry Players: Distribution by Number of Patents
Table 24.68 Leading Non-Industry Players: Distribution by Number of Patents
Table 24.69 Leading Patent Assignees: Distribution by Number of Patents
Table 24.70 Patent Analysis: Distribution by Patent Age
Table 24.71 Patent Analysis: Patent Valuation
Table 24.72 Publication Analysis: Distribution by Year of Publication, Since 2019
Table 24.73 Publication Analysis: Distribution by Type of Publication
Table 24.74 Key Journals: Distribution by Number of Publications
Table 24.75 Key Journals: Distribution by Journal Impact Factor
Table 24.76 Most Active Publisher: Distribution by Number of Publications
Table 24.77 Most Active Copyright Holder: Distribution by Number of Publications
Table 24.78 Publication Analysis: Emerging Focus Area
Table 24.79 Publication Analysis: Distribution by Therapeutic Area
Table 24.80 Publication Analysis: Distribution by Geography
Table 24.81 Partnerships and Collaborations: Cumulative Year-wise Trend, Since Pre-2016
Table 24.82 Partnerships and Collaborations: Distribution by Type of Partnership
Table 24.83 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since Pre-2016
Table 24.84 Partnerships and Collaborations: Distribution by Type of Partner
Table 24.85 Partnerships and Collaborations: Distribution by Type of Degrader
Table 24.86 Most Active Players: Distribution by Number of Partnerships
Table 24.87 Partnerships and Collaborations: Local and International Agreements
Table 24.88 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 24.89 Funding and Investment Analysis: Cumulative Year-wise Trend, Since 2014
Table 24.90 Funding and Investment Analysis: Distribution by Amount Invested, Since 2014 (USD Million)
Table 24.91 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Since 2018
Table 24.92 Funding and Investments: Distribution by Type of Funding and Amount Invested (USD Million)
Table 24.93 Year wise Distribution of Amount Invested by Type of Funding, Since 2018
Table 24.94 Funding and Investments: Distribution by Geography (Region)
Table 24.95 Funding and Investments: Distribution by Geography (Country)
Table 24.96 Most Active Players: Distribution by Number of Funding Instances
Table 24.97 Most Active Players: Distribution by Amount Raised (USD Million)
Table 24.98 Key Investors: Distribution by Number of Funding Instances
Table 24.99 Funding and Investments Summary, Since 2018 (USD Million)
Table 24.100 Global Targeted Protein Degradation Therapies Market, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
Table 24.101 Targeted Protein Degradation Therapies Market: Distribution by Type of Degrader
Table 24.102 Targeted Protein Degradation Therapies Market for SERDs: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.103 Targeted Protein Degradation Therapies Market for PROTACs: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.104 Targeted Protein Degradation Therapies Market for Molecular Glues: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.105 Targeted Protein Degradation Therapies Market: Distribution by Target Indication
Table 24.106 Targeted Protein Degradation Therapies Market for Breast Cancer: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.107 Targeted Protein Degradation Therapies Market for Multiple Myeloma: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.108 Targeted Protein Degradation Therapies Market: Distribution by Key Geographical Regions (USD Million)
Table 24.109 Targeted Protein Degradation Therapies Market in North America: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.110 Targeted Protein Degradation Therapies Market in the US: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.111 Targeted Protein Degradation Therapies Market in Canada: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.112 Targeted Protein Degradation Therapies Market in Europe: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.113 Targeted Protein Degradation Therapies Market in the UK: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.114 Targeted Protein Degradation Therapies Market in Germany: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.115 Targeted Protein Degradation Therapies Market in France: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.116 Targeted Protein Degradation Therapies Market in Spain: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.117 Targeted Protein Degradation Therapies Market in Italy: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.118 Targeted Protein Degradation Therapies Market in Asia-Pacific: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.119 Targeted Protein Degradation Therapies Market in China: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.120 Targeted Protein Degradation Therapies Market in South Korea: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.121 Targeted Protein Degradation Therapies Market in India: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.122 Targeted Protein Degradation Therapies Market in Japan: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.123 Targeted Protein Degradation Therapies Market in Australia: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.124 Targeted Protein Degradation Therapies Market in Rest of the World: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.125 Targeted Protein Degradation Therapies Market in Brazil: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.126 Targeted Protein Degradation Therapies Market in Israel: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.127 Targeted Protein Degradation Therapies Market: RAD1901 / Elacestrant / Orserdu Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.128 Targeted Protein Degradation Therapies Market: Vepedegestrant / ARV-471 Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.129 Targeted Protein Degradation Therapies Market: OP-1250 / OP-1250-301 / Palazestrant Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.130 Targeted Protein Degradation Therapies Market: LY3484356 / Imlunestrant Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.131 Targeted Protein Degradation Therapies Market: CC-92480 / BMS-986348 / Mezigdomide Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.132 Targeted Protein Degradation Therapies Market: Camizestrant / AZD9833 Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.133 Global Targeted Protein Degradation Technologies Market, Historical Trends (Since 2018), Base Scenario (USD Million)
Table 24.134 Global Targeted Protein Degradation Technologies Market, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.135 Targeted Protein Degradation Technologies Market: Distribution by Type of Payment Model Employed (USD Million)
Table 24.136 Targeted Protein Degradation Technologies Market for Upfront Payments, Historical Trends Since 2018, Base Scenario (USD Million)
Table 24.137 Targeted Protein Degradation Technologies Market for Upfront Payments, Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.138 Targeted Protein Degradation Technologies Market for Milestone Payments, Historical Trends, Since 2018, Base Scenario (USD Million)
Table 24.139 Targeted Protein Degradation Technologies Market for Milestone Payments, Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.1 Targeted Protein Degradation: List of Funding and Investments, Since 2014

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentations
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Targeted Protein Degradation Therapies Market Landscape
Figure 4.2 Executive Summary: Targeted Protein Degradation Technologies Market Landscape
Figure 4.3 Executive Summary: Clinical Trial Analysis
Figure 4.4 Executive Summary: Grants Analysis
Figure 4.5 Executive Summary: Patent Analysis
Figure 4.6 Executive Summary: Publication Analysis
Figure 4.7 Executive Summary: Partnerships and Collaborations
Figure 4.8 Executive Summary: Funding and Investments
Figure 4.9 Executive Summary: Therapies Market Forecast and Opportunity Analysis
Figure 4.10 Executive Summary: Technologies Market Forecast and Opportunity Analysis
Figure 5.1 Timeline of Induced Protein Degradation Field
Figure 5.2 Ubiquitin-Proteasome System Pathway
Figure 5.3 Types of Protein Degraders
Figure 5.4 Mechanism of Action of PROTAC
Figure 5.5 Advantages of PROTACs
Figure 5.6 Mechanism of Action of ENDTAC
Figure 5.7 Mechanism of Action of PHOTAC
Figure 5.8 Mechanism of Action of Hydrophobic Tag
Figure 5.9 Mechanism of Action of IMiD
Figure 5.10 Mechanism of Action of Molecular Glue
Figure 5.11 Mechanism of Action of SERD
Figure 5.12 Mechanism of Action of SNIPER
Figure 5.13 Protein Degradation: Targeted Therapeutic Areas
Figure 6.1 Targeted Protein Degradation Therapies: Distribution by Stage of Development
Figure 6.2 Targeted Protein Degradation Technologies: Distribution by Type of Degrader
Figure 6.3 Targeted Protein Degradation Therapies: Distribution by Biological Target
Figure 6.4 Targeted Protein Degradation Therapies: Distribution by Target Enzyme
Figure 6.5 Targeted Protein Degradation Therapies: Distribution by Target Indication
Figure 6.6 Targeted Protein Degradation Therapies: Distribution by Therapeutic Area
Figure 6.7 Targeted Protein Degradation Therapy Developers: Distribution by Year of Establishment
Figure 6.8 Targeted Protein Degradation Therapy Developers: Distribution by Company Size
Figure 6.9 Targeted Protein Degradation Therapy Developers: Distribution by Location of Headquarters (Region)
Figure 6.10 Targeted Protein Degradation Therapy Developers: Distribution by Year of Establishment and Location of Headquarters (Region)
Figure 6.11 Targeted Protein Degradation Therapy Developers: Distribution by Company Size and Location of Headquarters (Region)
Figure 6.12 Most Active Developers: Distribution by Number of Therapies and Stage of Development
Figure 7.1 Targeted Protein Degradation Technologies: Distribution by Type of Degrader Developed
Figure 7.2 Targeted Protein Degradation Technologies: Distribution by Protein Degradation Pathway
Figure 7.3 Targeted Protein Degradation Technologies: Distribution by Site of Degraded Protein
Figure 7.4 Targeted Protein Degradation Technologies: Distribution by Therapeutic Area
Figure 7.5 Targeted Protein Degradation Technologies: Distribution by Discovery Step Supported
Figure 7.6 Targeted Protein Degradation Technologies: Distribution by Availability of Computational Modeling Ability
Figure 7.7 Targeted Protein Degradation Technology Providers: Distribution by Year of Establishment
Figure 7.8 Targeted Protein Degradation Technology Providers: Distribution by Company Size
Figure 7.9 Targeted Protein Degradation Technology Providers: Distribution by Location of Headquarters (Region)
Figure 7.10 Targeted Protein Degradation Technology Providers: Distribution by Year of Establishment and Location of Headquarters (Region)
Figure 7.11 Targeted Protein Degradation Technology Providers: Distribution by Company Size and Location of Headquarters (Region)
Figure 8.1 Arvinas: Annual Revenues, Since FY 2019 (USD Million)
Figure 8.2 Bristol-Myers Squibb: Annual Revenues, Since FY 2019 (USD Billion)
Figure 8.3 C4 Therapeutics: Annual Revenues, Since FY 2019 (USD Million)
Figure 8.4 Radius Health: Annual Revenues, Since FY 2019 (USD Million)
Figure 8.5 AstraZeneca: Annual Revenues, Since FY 2019 (USD Billion)
Figure 8.6 Roche: Annual Revenues, Since FY 2019 (CHF Billion)
Figure 9.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2019
Figure 9.2 Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year, Since 2019
Figure 9.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 9.4 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Figure 9.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Since 2019
Figure 9.6 Clinical Trial Analysis: Distribution by Trial Status
Figure 9.7 Clinical Trial Analysis: Distribution by Patient Gender
Figure 9.8 Clinical Trial Analysis: Distribution by Target Indication
Figure 9.9 Clinical Trial Analysis: Distribution by Type of Trial Masking
Figure 9.10 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 9.11 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 9.12 Clinical Trial Analysis: Distribution by Design Allocation
Figure 9.13 Leading Industry Players: Distribution by Number of Registered Trials
Figure 9.14 Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 9.15 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Figure 9.16 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Figure 10.1 Grants Analysis: Cumulative Year-wise Trend, Since 2019
Figure 10.2 Grants Analysis: Cumulative Year-wise Trend of Grants by Amount Awarded (USD Million)
Figure 10.3 Grants Analysis: Distribution by Funding Institute Center
Figure 10.4 Grants Analysis: Distribution by Support Period
Figure 10.5 Grants Analysis: Distribution by Funding Institute Center and Support Period
Figure 10.6 Grants Analysis: Distribution by Type of Grant Application
Figure 10.7 Grants Analysis: Distribution by Purpose of Grant Award
Figure 10.8 Grants Analysis: Distribution by Activity Code (Series)
Figure 10.9 Grants Analysis: Distribution by Activity Code
Figure 10.10 Grants Analysis: Distribution by Study Section Involved
Figure 10.11 Most Popular NIH Departments: Distribution by Number of Grants
Figure 10.12 Prominent Program Officers: Distribution by Number of Grants
Figure 10.13 Popular Recipient Organizations: Distribution by Number of Grants
Figure 10.14 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
Figure 10.15 Popular Recipient Organizations: Distribution by States in the US
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Distribution by Patent Publication Year, Since 2019
Figure 11.3 Patent Analysis: Distribution by Patent Application Year, Since Pre-2019
Figure 11.4 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, Since 2019
Figure 11.5 Patent Analysis: Distribution by Patent Jurisdiction
Figure 11.6 Patent Analysis: Distribution by CPC Symbols
Figure 11.7 Patent Analysis: Cumulative Year-wise Trend by Type of Applicant
Figure 11.8 Leading Industry Players: Distribution by Number of Patents
Figure 11.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.10 Leading Patent Assignees: Distribution by Number of Patents
Figure 11.11 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 11.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 11.13 Patent Analysis: Distribution by Patent Age
Figure 11.14 Targeted Protein Degradation: Patent Valuation
Figure 12.1 Publication Analysis: Distribution by Year of Publication, Since 2019
Figure 12.2 Publication Analysis: Distribution by Type of Publication
Figure 12.3 Key Journals: Distribution by Number of Publications
Figure 12.4 Key Journals: Distribution by Journal Impact Factor
Figure 12.5 Most Active Publisher: Distribution by Number of Publications
Figure 12.6 Most Active Copyright Holder: Distribution by Number of Publications
Figure 12.7 Publication Analysis: Emerging Focus Area
Figure 12.8 Publication Analysis: Distribution by Therapeutic Area
Figure 12.9 Publication Analysis: Distribution by Geography
Figure 13.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since Pre-2016
Figure 13.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 13.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since Pre-2016
Figure 13.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 13.5 Partnerships and Collaborations: Distribution by Type of Degrader
Figure 13.6 Most Active Players: Distribution by Number of Partnerships
Figure 13.7 Partnership and Collaborations: Local and International Agreements
Figure 13.8 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 14.1 Funding and Investment Analysis: Cumulative Year-wise Trend, Since 2014
Figure 14.2 Funding and Investment Analysis: Distribution by Amount Invested, Since 2014 (USD Million)
Figure 14.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Since 2018
Figure 14.4 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding (USD Million)
Figure 14.5 Year-wise Distribution of Amount Invested by Type of Funding, Since 2018
Figure 14.6 Funding and Investment Analysis: Distribution by Geography (Region)
Figure 14.7 Funding and Investment Analysis: Distribution by Geography (Country)
Figure 14.8 Most Active Players: Distribution by Number of Funding Instances
Figure 14.9 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 14.10 Leading Investors: Distribution by Number of Funding Instances
Figure 14.11 Funding and Investment Summary, Since 2018 (USD Million)
Figure 15.1 Targeted Protein Degradation: Market Drivers
Figure 15.2 Targeted Protein Degradation: Market Restraints
Figure 15.3 Targeted Protein Degradation: Market Opportunities
Figure 15.4 Targeted Protein Degradation: Market Challenges
Figure 16.1 Global Targeted Protein Degradation Therapies Market, Till 2035 (USD Million)
Figure 16.2 Global Targeted Protein Degradation Therapies Market, Till 2035: Conservative Scenario (USD Million)
Figure 16.3 Global Targeted Protein Degradation Therapies Market, Till 2035: Optimistic Scenario (USD Million)
Figure 17.1 Targeted Protein Degradation Therapies Market: Distribution by Type of Degrader
Figure 17.2 Targeted Protein Degradation Therapies Market for SERDs: Forecasted Estimates (Till 2035) (USD Million)
Figure 17.3 Targeted Protein Degradation Therapies Market for PROTACs: Forecasted Estimates (Till 2035) (USD Million)
Figure 17.4 Targeted Protein Degradation Therapies Market for Molecular Glues: Forecasted Estimates (Till 2035) (USD Million)
Figure 18.1 Targeted Protein Degradation Therapies Market: Distribution by Target Indication
Figure 18.2 Targeted Protein Degradation Therapies Market for Breast Cancer: Forecasted Estimates (Till 2035) (USD Million)
Figure 18.3 Targeted Protein Degradation Therapies Market for Multiple Myeloma: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.1 Targeted Protein Degradation Therapies Market: Distribution by Key Geographical Regions (USD Million)
Figure 19.2 Targeted Protein Degradation Therapies Market in North America: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.3 Targeted Protein Degradation Therapies Market in the US: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.4 Targeted Protein Degradation Therapies Market in Canada: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.5 Targeted Protein Degradation Therapies Market in Europe: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.6 Targeted Protein Degradation Therapies Market in the UK: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.7 Targeted Protein Degradation Therapies Market in Germany: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.8 Targeted Protein Degradation Therapies Market in France: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.9 Targeted Protein Degradation Therapies Market in Spain: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.10 Targeted Protein Degradation Therapies Market in Italy: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.11 Targeted Protein Degradation Therapies Market in Asia-Pacific: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.12 Targeted Protein Degradation Therapies Market in China: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.13 Targeted Protein Degradation Therapies Market in South Korea: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.14 Targeted Protein Degradation Therapies Market in India: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.15 Targeted Protein Degradation Therapies Market in Japan: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.16 Targeted Protein Degradation Therapies Market in Australia: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.17 Targeted Protein Degradation Therapies Market in Rest of the World: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.18 Targeted Protein Degradation Therapies Market in Brazil: Forecasted Estimates (Till 2035) (USD Million)
Figure 19.19 Targeted Protein Degradation Therapies Market in Israel: Forecasted Estimates (Till 2035) (USD Million)
Figure 20.1 Targeted Protein Degradation Therapies Market: RAD1901 / Elacestrant / Orserdu Sales Forecast, Till 2035 (USD Million)
Figure 20.2 Targeted Protein Degradation Therapies Market: Vepedegestrant / ARV-471 Sales Forecast, Till 2035 (USD Million)
Figure 20.3 Targeted Protein Degradation Therapies Market: OP-1250 / OP-1250-301 / Palazestrant Sales Forecast, Till 2035 (USD Million)
Figure 20.4 Targeted Protein Degradation Therapies Market: LY3484356 / Imlunestrant Sales Forecast, Till 2035 (USD Million)
Figure 20.5 Targeted Protein Degradation Therapies Market: CC-92480 / BMS-986348 / Mezigdomide Sales Forecast, Till 2035 (USD Million)
Figure 20.6 Targeted Protein Degradation Therapies Market: Camizestrant / AZD9833 Sales Forecast, Till 2035 (USD Million)
Figure 21.1 Licensing Agreements: Distribution of Financial Components
Figure 21.2 Licensing Agreements: Illustrative Scenario based Opportunity Estimation
Figure 21.3 Global Targeted Protein Degradation Technologies Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 21.4 Global Targeted Protein Degradation Technologies Market, Till 2035: Conservative Scenario (USD Million)
Figure 21.5 Global Targeted Protein Degradation Technologies Market, Till 2035: Optimistic Scenario (USD Million)
Figure 21.6 Targeted Protein Degradation Technologies Market: Distribution by Type of Payment Model Employed
Figure 21.7 Targeted Protein Degradation Technologies Market for Upfront Payments, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 21.8 Targeted Protein Degradation Technologies Market for Milestone Payments, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
Figure 23.1 Conclusion: Targeted Protein Degradation Therapies Market Landscape
Figure 23.2 Conclusion: Targeted Protein Degradation Technologies Market Landscape
Figure 23.3 Conclusion: Clinical Trial Analysis
Figure 23.4 Conclusion: Grants Analysis
Figure 23.5 Conclusion: Patent Analysis
Figure 23.6 Conclusion: Publication Analysis
Figure 23.7 Conclusion: Partnerships and Collaborations
Figure 23.8 Conclusion: Funding and Investments
Figure 23.9 Conclusion: Therapies Market Forecast and Opportunity Analysis
Figure 23.10 Conclusion: Technologies Market Forecast and Opportunity Analysis

Targeted Protein Degradation Market Distribution by Type of Degrader, Target Indication, Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World )

Description

Table of Contents

List of Tables

TARGETED PROTEIN DEGRADATION MARKET: OVERVIEW

TARGETED PROTEIN DEGRADATION MARKET: GROWTH AND TRENDS

TARGETED PROTEIN DEGRADATION MARKET: KEY INSIGHTS

TARGETED PROTEIN DEGRADATION MARKET: KEY SEGMENTS

Example Players in the Targeted Protein Degradation Market

TARGETED PROTEIN DEGRADATION MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

1.1. Market Overview

2. RESEARCH METHODOLOGY

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

4. EXECUTIVE SUMMARY

5. INTRODUCTION

6. MARKET LANDSCAPE: TARGETED PROTEIN DEGRADATION THERAPIES

7. MARKET LANDSCAPE: TARGETED PROTEIN DEGRADATION TECHNOLOGIES

8. COMPANY PROFILES

9. CLINICAL TRIAL ANALYSIS

10. GRANTS ANALYSIS

11. PATENT ANALYSIS

12. PUBLICATION ANALYSIS

13. PARTNERSHIPS AND COLLABORATIONS

14. FUNDING AND INVESTMENTS

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

16. GLOBAL TARGETED PROTEIN DEGRADATION THERAPIES MARKET

17. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, BY TYPE OF DEGRADER

18. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, BY TARGET INDICATION

19. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, BY KEY GEOGRAPHICAL REGIONS

20. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, SALES FORECAST OF DRUGS

21. GLOBAL TARGETED PROTEIN DEGRADATION TECHNOLOGIES MARKET

22. EXECUTIVE INSIGHTS

23. CONCLUSION

24. APPENDIX 1: TABULATED DATA

25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

26. APPENDIX 3: LIST OF FUNDING AND INVESTMENTS

List of Tables

List of Figures